alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Alemtuzumab for relapsing-remitting multiple sclerosis.
In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...
متن کاملEmerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.
Newer outcome-based assessment methods have been developed that complement and improve upon the ability of historical clinical and magnetic resonance imaging (MRI) outcome measures to measure multiple sclerosis (MS) disease activity, patient functionality, treatment efficacy, and the risk of MS disease progression. These newer MS outcome assessments include instruments to evaluate cognitive fun...
متن کاملAlemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
BACKGROUND Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded phase 2 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzumab reduced relapse rate and the risk of sustained accumulation of disability compared with subcutaneous interferon beta-1a, and the mean expa...
متن کاملAlemtuzumab vs. interferon beta-1a in early multiple sclerosis.
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a dis...
متن کاملNatalizumab plus interferon beta-1a for relapsing multiple sclerosis.
BACKGROUND Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at leas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2017
ISSN: 1465-1858
DOI: 10.1002/14651858.cd010968.pub2